Altimmune Revenue vs. Current Valuation
| ALT Stock | USD 4.01 0.04 0.99% |
Total Revenue | First Reported 2005-09-30 | Previous Quarter 5 K | Current Value 5 K | Quarterly Volatility 2.8 M |
For Altimmune profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Altimmune to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Altimmune utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Altimmune's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Altimmune over time as well as its relative position and ranking within its peers.
Altimmune | Build AI portfolio with Altimmune Stock |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altimmune. If investors know Altimmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altimmune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Altimmune is measured differently than its book value, which is the value of Altimmune that is recorded on the company's balance sheet. Investors also form their own opinion of Altimmune's value that differs from its market value or its book value, called intrinsic value, which is Altimmune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altimmune's market value can be influenced by many factors that don't directly affect Altimmune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Altimmune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Altimmune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altimmune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Altimmune Current Valuation vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Altimmune's current stock value. Our valuation model uses many indicators to compare Altimmune value to that of its competitors to determine the firm's financial worth. Altimmune is rated fifth in revenue category among its peers. It also is rated fifth in current valuation category among its peers reporting about 11,386 of Current Valuation per Revenue. At this time, Altimmune's Total Revenue is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Altimmune by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Altimmune Revenue vs. Competition
Altimmune is rated fifth in revenue category among its peers. Market size based on revenue of Health Care industry is presently estimated at about 260.78 Million. Altimmune adds roughly 20,000 in revenue claiming only tiny portion of equities under Health Care industry.
Altimmune Current Valuation vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Altimmune |
| = | 20 K |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Altimmune |
| = | 227.72 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Altimmune Current Valuation vs Competition
Altimmune is rated fifth in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is presently estimated at about 3.06 Billion. Altimmune holds roughly 227.72 Million in current valuation claiming about 7% of equities under Health Care industry.
Altimmune Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Altimmune, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Altimmune will eventually generate negative long term returns. The profitability progress is the general direction of Altimmune's change in net profit over the period of time. It can combine multiple indicators of Altimmune, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -4.5 M | -4.3 M | |
| Operating Income | -92.9 M | -88.2 M | |
| Income Before Tax | -109.3 M | -114.8 M | |
| Net Loss | -85.6 M | -81.3 M | |
| Income Tax Expense | 278.2 K | 264.3 K | |
| Total Other Income Expense Net | 9.3 M | 9.8 M | |
| Net Loss | -85.6 M | -81.3 M | |
| Non Operating Income Net Other | -154 K | -146.3 K | |
| Net Loss | -76.2 M | -72.4 M | |
| Interest Income | 9.3 M | 9.7 M | |
| Net Interest Income | 9.3 M | 9.7 M | |
| Change To Netincome | 9.5 M | 10.3 M | |
| Net Loss | (1.20) | (1.27) | |
| Income Quality | 0.97 | 0.95 | |
| Net Income Per E B T | 0.90 | 0.58 |
Altimmune Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Altimmune. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Altimmune position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Altimmune's important profitability drivers and their relationship over time.
Altimmune Earnings Estimation Breakdown
The calculation of Altimmune's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Altimmune is estimated to be -0.2629 with the future projection ranging from a low of -0.31 to a high of -0.22. Please be aware that this consensus of annual earnings estimates for Altimmune is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.31 Lowest | Expected EPS | -0.22 Highest |
Altimmune Earnings Projection Consensus
Suppose the current estimates of Altimmune's value are higher than the current market price of the Altimmune stock. In this case, investors may conclude that Altimmune is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Altimmune's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 9 | 79.28% | 0.0 | -0.2629 | -1.07 |
Altimmune Earnings per Share Projection vs Actual
Actual Earning per Share of Altimmune refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Altimmune predict the company's earnings will be in the future. The higher the earnings per share of Altimmune, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Altimmune Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Altimmune, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Altimmune should always be considered in relation to other companies to make a more educated investment decision.Altimmune Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Altimmune's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2025-11-06 | 2025-09-30 | -0.27 | -0.21 | 0.06 | 22 | ||
2025-08-12 | 2025-06-30 | -0.31 | -0.27 | 0.04 | 12 | ||
2025-05-07 | 2025-03-31 | -0.3417 | -0.26 | 0.0817 | 23 | ||
2025-03-25 | 2024-12-31 | -0.3351 | -0.33 | 0.0051 | 1 | ||
2024-11-05 | 2024-09-30 | -0.35 | -0.3214 | 0.0286 | 8 | ||
2024-08-08 | 2024-06-30 | -0.34 | -0.35 | -0.01 | 2 | ||
2024-05-14 | 2024-03-31 | -0.37 | -0.34 | 0.03 | 8 | ||
2024-03-27 | 2023-12-31 | -0.43 | -0.33 | 0.1 | 23 | ||
2023-11-07 | 2023-09-30 | -0.42 | -0.39 | 0.03 | 7 | ||
2023-08-10 | 2023-06-30 | -0.46 | -0.32 | 0.14 | 30 | ||
2023-05-11 | 2023-03-31 | -0.48 | -0.4 | 0.08 | 16 | ||
2023-02-28 | 2022-12-31 | -0.5 | -0.43 | 0.07 | 14 | ||
2022-11-10 | 2022-09-30 | -0.5 | -0.48 | 0.02 | 4 | ||
2022-08-11 | 2022-06-30 | -0.47 | -0.42 | 0.05 | 10 | ||
2022-05-12 | 2022-03-31 | -0.58 | -0.44 | 0.14 | 24 | ||
2022-03-15 | 2021-12-31 | -0.65 | -0.57 | 0.08 | 12 | ||
2021-11-09 | 2021-09-30 | -0.39 | -0.81 | -0.42 | 107 | ||
2021-08-10 | 2021-06-30 | -0.5 | -0.6 | -0.1 | 20 | ||
2021-05-17 | 2021-03-31 | -0.47 | -0.38 | 0.09 | 19 | ||
2021-02-25 | 2020-12-31 | -0.75 | -0.17 | 0.58 | 77 | ||
2020-11-09 | 2020-09-30 | -0.76 | -0.54 | 0.22 | 28 | ||
2020-08-11 | 2020-06-30 | -0.4 | -0.94 | -0.54 | 135 | ||
2020-05-13 | 2020-03-31 | -0.32 | -0.26 | 0.06 | 18 | ||
2020-03-27 | 2019-12-31 | -0.26 | -0.25 | 0.01 | 3 | ||
2019-11-13 | 2019-09-30 | -0.19 | -0.73 | -0.54 | 284 | ||
2019-08-13 | 2019-06-30 | -0.25 | -0.26 | -0.01 | 4 | ||
2019-04-01 | 2019-03-31 | -2.8 | -0.27 | 2.53 | 90 | ||
2019-03-31 | 2018-12-31 | -2.8 | -2.34 | 0.46 | 16 | ||
2018-11-13 | 2018-09-30 | -3.6 | -2.34 | 1.26 | 35 | ||
2018-08-14 | 2018-06-30 | -4.5 | -4.8 | -0.3 | 6 | ||
2018-05-15 | 2018-03-31 | -15 | -7.5 | 7.5 | 50 | ||
2018-03-28 | 2017-12-31 | -15 | -17.4 | -2.4 | 16 | ||
2017-11-09 | 2017-09-30 | -8.4 | -10.2 | -1.8 | 21 | ||
2017-03-14 | 2016-12-31 | 0 | 1.14 | 1.14 | 0 | ||
2016-11-04 | 2016-09-30 | 0 | 1.67 | 1.67 | 0 | ||
2016-08-04 | 2016-06-30 | 0 | 0.12 | 0.12 | 0 | ||
2016-05-09 | 2016-03-31 | 0 | 0.02 | 0.02 | 0 | ||
2016-03-11 | 2015-12-31 | 0 | -0.01 | -0.01 | 0 | ||
2015-11-06 | 2015-09-30 | 0 | -0.02 | -0.02 | 0 | ||
2015-08-05 | 2015-06-30 | 0 | -0.04 | -0.04 | 0 | ||
null | null | null | null | null | 0 | ||
2014-11-06 | 2014-09-30 | -7.5 | -24.0 | -16.5 | 220 | ||
2014-08-04 | 2014-06-30 | -16.5 | -3.0 | 13.5 | 81 | ||
2014-05-08 | 2014-03-31 | -18 | -12.0 | 6.0 | 33 | ||
2014-03-11 | 2013-12-31 | -15 | -24.0 | -9.0 | 60 | ||
2013-11-07 | 2013-09-30 | -10.5 | -24.0 | -13.5 | 128 | ||
2013-08-07 | 2013-06-30 | -9 | -6.0 | 3.0 | 33 | ||
2013-05-08 | 2013-03-31 | -15 | -12.0 | 3.0 | 20 | ||
2013-03-13 | 2012-12-31 | -12 | -6.0 | 6.0 | 50 | ||
2012-11-06 | 2012-09-30 | -9 | -1.3275 | 7.6725 | 85 | ||
2012-08-07 | 2012-06-30 | -9 | -6.0 | 3.0 | 33 | ||
2012-05-08 | 2012-03-31 | -15 | -18.0 | -3.0 | 20 | ||
2012-03-08 | 2011-12-31 | -32 | 3.0 | 35.0 | 109 | ||
2011-11-09 | 2011-09-30 | -25 | -0.2085 | 24.7915 | 99 | ||
2011-08-10 | 2011-06-30 | -31.5 | -15.0 | 16.5 | 52 | ||
2011-05-11 | 2011-03-31 | -29 | -12.0 | 17.0 | 58 | ||
2011-03-28 | 2010-12-31 | -26 | -138.0 | -112.0 | 430 | ||
2010-11-11 | 2010-09-30 | -52 | -42.0 | 10.0 | 19 | ||
2010-08-12 | 2010-06-30 | -61.5 | -66.0 | -4.5 | 7 | ||
2010-05-11 | 2010-03-31 | -51 | -84.0 | -33.0 | 64 | ||
2010-03-23 | 2009-12-31 | -61.5 | -60.0 | 1.5 | 2 | ||
2009-11-12 | 2009-09-30 | -57 | -150.0 | -93.0 | 163 | ||
2009-08-13 | 2009-06-30 | -54 | -72.0 | -18.0 | 33 | ||
2009-05-15 | 2009-03-31 | -60 | -69.0 | -9.0 | 15 | ||
2009-03-30 | 2008-12-31 | -78 | -51.0 | 27.0 | 34 | ||
2008-11-13 | 2008-09-30 | -78 | -60.0 | 18.0 | 23 |
Use Altimmune in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Altimmune position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Altimmune will appreciate offsetting losses from the drop in the long position's value.Altimmune Pair Trading
Altimmune Pair Trading Analysis
The ability to find closely correlated positions to Altimmune could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Altimmune when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Altimmune - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Altimmune to buy it.
The correlation of Altimmune is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Altimmune moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Altimmune moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Altimmune can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Altimmune position
In addition to having Altimmune in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Blockchain Thematic Idea Now
Blockchain
Companies across muliple sectors and different technology products and services that are engaged in some capacity with blockchain technolgoy or evolution of cryptocurrency. The Blockchain theme has 28 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Blockchain Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Altimmune Stock Analysis
When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.